Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Titel:
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Auteur:
Mai, Elias K Goldschmidt, Hartmut Miah, Kaya Bertsch, Uta Besemer, Britta Hänel, Mathias Krzykalla, Julia Fenk, Roland Schlenzka, Jana Munder, Markus Dürig, Jan Blau, Igor W Huhn, Stefanie Hose, Dirk Jauch, Anna Kunz, Christina Mann, Christoph Weinhold, Niels Scheid, Christof Schroers, Roland von Metzler, Ivana Schieferdecker, Aneta Thomalla, Jörg Reimer, Peter Mahlberg, Rolf Graeven, Ullrich Kremers, Stephan Martens, Uwe M Kunz, Christian Hensel, Manfred Benner, Axel Seidel-Glätzer, Andrea Weisel, Katja C Raab, Marc S Salwender, Hans J
Verschenen in:
The Lancet. Haematology
Paginering:
Jaargang 11 () nr. 2 pagina's e101-e113
Jaar:
2024
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license